English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Background  To investigate the guidance selection of docetaxel (D), cisplatin (DDP) (C), and 5-fluorouracil (5-FU) (F) as individual chemotherapy agents via joint detection of  ERCC1 ,  TUBB3 , and  TYMS  genes in patients with advanced gastric cancer (AGC).    Method  Clinical data of 120 patients with AGC who enrolled in our hospital between May 2009 and May 2012 were analyzed. These patients were randomly assigned to experimental and control groups. The mRNA expression of  ERCC1 ,  TUBB3 , and  TYMS  was measured by DNA chip technology in the experimental group. Different chemotherapies were administered according to the mRNA expression levels of the three genes, while DCF chemotherapy was directly applied to the control group. Correlation between the three genes’ mRNA levels, efficiency rate, the median time to progression (MTP), median survival time (MST) and adverse reactions was evaluated.    Results  As a result, there was a significant correlation between  ERCC1  and  TUBB3  mRNA expression ( P  = 0.005), but no obvious correlation between  TUBB3  and  TYMS  or  ERCC1  and  TYMS . There was also no significant difference in the efficiency rate of chemotherapy (50% versus 55%;  P  = 0.357) and the MTP (10 months versus 7 months;  P  = 0.091) between the two groups. However, there was obvious significance in MST (13.7 months versus 11.6 months;  P  = 0.004). Additionally, the experimental group provided us with a more effective way for controlling adverse reactions to chemotherapy.    Conclusion  Combination regimen of D, C, and F in AGC patients according to their  ERCC1 ,  TUBB3 , and  TYMS  mRNA expression level may reduce adverse reactions and improve MST.

european journal of medical research

RETRACTED ARTICLE: Joint detection of ERCC1, TUBB3, and TYMS guidance selection of docetaxel, 5-fluorouracil and cisplatin (DDP) individual chemotherapy in advanced gastric cancer patients